Actively Recruiting
Recovering From COVID-19 Lingering Symptoms Adaptive Integrative Medicine Trial - Effect of Hyperbaric Oxygen Therapy for the Treatment of Post COVID Condition
Led by University Health Network, Toronto · Updated on 2026-02-23
120
Participants Needed
1
Research Sites
208 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The RECLAIM study platform will be used to explore whether the use of Hyperbaric Oxygen therapy (HBOT) improves the symptoms of post covid cognitive dysfunction. Hyperbaric oxygen therapy is a well-established medical treatment. HBOT promotes healing by delivering a high concentration of oxygen into the body. This high level of oxygen has a number of known benefits, such as growth of new blood vessels, as well as regulating immune and inflammation responses. It helps protect the brain and other nervous tissue from inflammation. HBOT may also have antiviral effects. Collectively, it has the potential to target the underlying mechanisms believed to play a critical role in the development of Long COVID. Many individuals with Long COVID complain of fatigue, brain fog, muscle aches and other symptoms. There is evidence to suggest that these symptoms may be a problem with the blood vessels, resulting in abnormal delivery of oxygen to tissues. Thus, our group is investigating whether HBOT improves post-COVID cognitive dysfunction.
CONDITIONS
Official Title
Recovering From COVID-19 Lingering Symptoms Adaptive Integrative Medicine Trial - Effect of Hyperbaric Oxygen Therapy for the Treatment of Post COVID Condition
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older
- Positive COVID-19 test by nasopharyngeal swab RT-PCR, antibody, or antigen test at least 3 months before randomization, or presumed COVID-19 diagnosed by investigator after October 15, 2019
- Treated with standard care therapies for at least 4 weeks before trial entry
- Lingering COVID-19 symptoms lasting beyond 3 months from onset and lasting at least 2 months
- Lingering symptoms present at randomization including self-reported cognitive dysfunction
- Female patients of childbearing potential who are sexually active must agree to use effective contraception or practice abstinence during treatment
- Ability to provide informed consent and comply with study requirements
- Confirmed ability to travel to one of the three treatment sites
You will not qualify if you...
- History of mechanical ventilation or extracorporeal membrane oxygen (ECMO) for COVID-19
- Current end-organ failure, organ transplantation, or acute care hospital admission
- Contraindications to study interventions
- Co-enrollment in another interventional trial (observational studies allowed)
- Currently pregnant or breastfeeding
- Pneumothorax
- Poorly controlled seizure disorder
- Chronic sinusitis
- Chronic or acute otitis media
- Major eardrum trauma
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University Health Network
Toronto, Ontario, Canada, M5G 2C4
Actively Recruiting
Research Team
R
RECLAIM CONTACT RECLAIM contact line
CONTACT
A
Andrew Janes, MSc
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here